LIXTE Biotechnology Holdings (NASDAQ: LIXT) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, outlining a year of significant transformation. The clinical-stage pharmaceutical and med-tech company reported progress in advancing its lead compound LB-100, a first-in-class PP2A inhibitor, and highlighted the expansion of clinical trials to additional sites with increased patient enrollment. The company also completed the acquisition of Liora Technologies Europe Ltd., a move designed to enhance its cancer treatment platform through proton therapy innovation. To strengthen its financial position, LIXTE raised more than $11 million during the year, supporting its continued growth in oncology.
LIXTE’s lead compound LB-100 is being evaluated for its potential to enhance chemotherapies and immunotherapies by targeting the PP2A enzyme, a key regulator in cancer cell survival. The compound is currently in proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. According to the company, LB-100 has demonstrated tolerability at doses associated with anti-cancer activity, positioning it as a promising candidate in the emerging field of activation lethality. The company’s patent portfolio covers this novel approach, which aims to exploit vulnerabilities in cancer cells.
The acquisition of Liora Technologies Europe Ltd. adds a complementary technology to LIXTE’s pipeline. Liora is developing the LiGHT System, an electronically controlled proton therapy system designed to treat tumors with what the company believes are significant advantages over existing proton therapy technologies. This move signals LIXTE’s expansion beyond small-molecule drug development into advanced medical devices for cancer treatment.
LIXTE’s 2025 Form 10-K filing provides detailed financial and operational updates, including the leadership changes that occurred during the year. The company’s efforts to streamline its clinical operations and secure additional funding are expected to support the ongoing development of LB-100 and the integration of Liora’s technology. For more information on the full press release, visit this link. Additional details about LIXTE’s pipeline and platforms are available at www.lixte.com.
The company notes that forward-looking statements in the filing involve risks and uncertainties, including those detailed in the Risk Factors section of its SEC filings. Investors are cautioned not to place undue reliance on these statements, as actual results may differ materially. LIXTE undertakes no obligation to update forward-looking statements except as required by law. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
